Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration
Abstract
Importance
Geographic atrophy (GA) secondary to age-related macular degeneration is a leading cause of visual disability in older individuals. A phase 2 trial suggested that lampalizumab, a selective complement factor D inhibitor, reduced the rate of GA enlargement, warranting phase 3 trials.Objective
To assess the safety and efficacy of lampalizumab vs sham procedure on enlargement of GA.Design, Setting, and...
Paper Details
Title
Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration
Published Date
Jun 1, 2018
Journal
Volume
136
Issue
6
Pages
666 - 666
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History